Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies
Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.Introduction:
Bendamustine, typically in combination with rituximab, is an effective treatment for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. Despite its acceptable short-term toxicity profile, long-term toxicities are less well established. This study investigated the long-term adverse effects of bendamustine and responses to subsequent treatments.Patients and Methods:
Charts of 194 patients were retrospectively reviewed; 54% had received prior treatment (76% attained complete response [CR] or partial response [PR]).Results:
Patients who did not achieve a CR or PR did not respond well to subsequent treatments. Malignancies following bendamustine were diagnosed in 11% (21) of patients (first line  and salvage ), including squamous (8) or basal cell (4) skin cancers; prostate cancer (3), renal cancer (3), bladder cancer (2), melanoma (2), lung cancer (1), and histiocytic sarcoma (1). There were no occurrences of therapy-related myelodysplastic syndrome or acute myelogenous leukemia reported. Infections occurred in 63% of patients; however, no deaths were attributable to bendamustine.Conclusion:
Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies.